SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Apr 6, 2020

Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: April 6, 2020 · CIK: 0001536196 · Accession: 0001213900-20-008638

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237443

Date
April 6, 2020
Author
CAN-FITE BIOPHARMA
Form
CORRESP
Company
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)

Letter

Can-Fite BioPharma Ltd.

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

April 6, 2020

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Can-Fite BioPharma Ltd.

Registration Statement on Form F-1

File No. 333-237443

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-237443) of the Company (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:00 a.m., Eastern Time, on April 7, 2020 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

Very truly
yours,
CAN-FITE BIOPHARMA
LTD.

Show Raw Text
CORRESP
1
filename1.htm

Can-Fite BioPharma Ltd.

10 Bareket
Street

Kiryat Matalon,
P.O. Box 7537

Petach-Tikva
4951778, Israel

April 6, 2020

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Can-Fite BioPharma Ltd.

        Registration Statement on Form F-1

        File No. 333-237443

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act
of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) hereby respectfully requests that the effectiveness
of the Registration Statement on Form F-1 (File No. 333-237443) of the Company (the “Registration Statement”)
be accelerated so that the Company’s Registration Statement will become effective at 9:00 a.m., Eastern Time, on April 7,
2020 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it
be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP,
by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request
for acceleration.

Very truly
yours,

CAN-FITE BIOPHARMA
LTD.

By: /s/ Pnina Fishman, Ph.D.

Name: Pnina Fishman, Ph.D.

Title: Chief Executive Officer

cc: Gary Emmanuel (McDermott Will & Emery LLP)